Cite

    Forsyth, S., Schroeder, P., Geib, J., Vrishabhendra, L., Konstantinidis, D. G., LaSalvia, K., Ribadeneira, M. D., Wu, E., Kelly, P., & Kalfa, T. A. (2022). safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial. Clinical pharmacology in drug development, 11(5), 654–665. http://access.bl.uk/ark:/81055/vdc_100154237929.0x000008